A phase Ib trial of ZEN 3694 in combination with enzalutemide as second-line therapy in metastatic castrate resistent prostate cancer patients

Trial Profile

A phase Ib trial of ZEN 3694 in combination with enzalutemide as second-line therapy in metastatic castrate resistent prostate cancer patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs ZEN 3694 (Primary) ; Enzalutamide
  • Indications Prostate cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors Zenith Epigenetics Corp
  • Most Recent Events

    • 21 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top